Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTABARBITAL SODIUM vs BUTABARB
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.
Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.
Preoperative sedation,Daytime sedation,Insomnia (short-term treatment),Status epilepticus (adjunct),Withdrawal syndrome (off-label)
Sedative,Hypnotic,Anticonvulsant,Preoperative anxiety
Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.
15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.
Terminal elimination half-life: 30-50 hours; accumulates with repeated dosing, prolonged in hepatic impairment
Terminal elimination half-life is 30-60 hours (mean ~40 hours) in adults with normal renal and hepatic function. Longer in elderly or patients with liver disease.
Primarily hepatic via CYP2C9, CYP2C19, and CYP3A4; conjugated with glucuronic acid; excreted renally.
Hepatic metabolism via CYP2C9 and CYP2C19; minor pathways involve glucuronidation.
Renal: 50-70% as metabolites (hydroxylated and conjugated forms), 5-10% unchanged; fecal: minor (<5%)
Renal excretion of unchanged drug and metabolites. Approximately 70-80% of a dose is eliminated in urine as metabolites (hydroxy and glucuronide conjugates) and <5% as parent drug. Minimal biliary/fecal elimination (<5%).
25-35%, primarily to albumin
Approximately 20-25% bound to plasma proteins (albumin).
0.5-0.8 L/kg; distributes widely into tissues, crosses blood-brain barrier
0.5-0.6 L/kg in adults. Higher Vd suggests distribution into total body water and tissues; may increase in obesity.
Oral: 80-100% (rapid absorption); IM: complete
Oral: 95-100% (well absorbed). Rectal: 80-90%. IM: 80-100%.
Contraindicated in severe renal impairment (e GFR <30 m L/min). For e GFR 30-50 m L/min: reduce dose by 25% and monitor for CNS depression. e GFR >50 m L/min: no adjustment.
e GFR 30-50 m L/min: reduce dose by 25%. e GFR <30 m L/min: avoid use or use 50% reduction with caution.
Contraindicated in Child-Pugh Class C. Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75% or use alternative. Avoid in severe hepatic impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
Not recommended for children <6 years. For children 6-12 years: sedative 5-15 mg orally 3-4 times daily; hypnotic not typically used. For adolescents >12 years: adult dosing with caution. Maximum single dose: 30 mg. Weight-based: 2-3 mg/kg/day divided every 6-8 hours, not to exceed 100 mg/day.
0.5-1 mg/kg/dose orally every 6-8 hours; maximum 30 mg/dose. Not recommended for children under 6 years.
Start with lowest effective dose (e.g., 15 mg orally for sedation). Maximum dose: 50 mg per dose. Caution due to increased sensitivity, risk of falls, and cognitive impairment. Avoid hypnotic use. Consider non-barbiturate alternatives.
Initiate at 7.5-15 mg orally 2-3 times daily; increase slowly. Avoid in frail elderly. Monitor for paradoxical excitation.
Barbiturates are habit-forming. Tolerance, psychological and physical dependence may occur. Withdrawal symptoms include delirium, convulsions, and death. Abrupt cessation after prolonged use is not recommended.
May be habit forming; potential for abuse and dependence. Abrupt discontinuation may precipitate life-threatening withdrawal symptoms.
Respiratory depression risk; use caution in hepatic impairment, renal impairment, elderly, or debilitated patients; avoid abrupt discontinuation; may cause paradoxical excitement; monitor for hypersensitivity reactions.
Respiratory depression, especially when combined with other CNS depressants; tolerance and dependence; withdrawal seizures; use with caution in hepatic impairment and elderly.
Hypersensitivity to barbiturates, porphyria, severe respiratory disease, severe hepatic impairment, history of addiction to sedative-hypnotics.
Hypersensitivity to barbiturates, porphyria, severe respiratory insufficiency, history of substance abuse.
Avoid grapefruit juice as it may alter metabolism. Limit or avoid alcohol; concurrent use increases CNS depression risk. Take with food if GI upset occurs; avoid high-fat meals as they may slow absorption.
Avoid grapefruit juice as it may inhibit metabolism and increase sedative effects. Take with food if gastrointestinal upset occurs. Limit caffeine intake as it may reduce sedative efficacy.
First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third trimester: Neonatal withdrawal syndrome, respiratory depression, and hemorrhagic disease due to vitamin K deficiency. FDA Category D.
Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, and cardiovascular anomalies. Second and third trimesters: Potential for fetal dependence, withdrawal syndrome, and impaired brain development. Chronic use may cause fetal growth restriction and preterm birth.
Excreted in breast milk; M/P ratio estimated 0.3-0.5. Risk of infant sedation, poor feeding, and withdrawal. Contraindicated in breastfeeding unless essential. Monitor for drowsiness, weight gain, and developmental milestones.
Barbiturates are excreted into breast milk in low concentrations. M/P ratio is approximately 0.5-0.6. Chronic high-dose use may lead to infant sedation and difficulty feeding. Monitor infant for signs of drowsiness, lethargy, or poor suckling. Use caution, especially in neonates or preterm infants.
Increased clearance (up to 50% higher) in pregnancy, especially third trimester. Dose may need to be increased by 30-50% to maintain therapeutic effect. Monitor serum levels and adjust to minimum effective dose.
Pregnancy induces hepatic microsomal enzymes, increasing barbiturate metabolism. Higher doses (increased by 30-50%) may be required to maintain therapeutic levels. Monitor serum drug levels if needed, especially in third trimester. Postpartum, reduce dose to prepregnancy levels to avoid toxicity.
Barbiturate with rapid onset used for preoperative sedation and seizure control. Respiratory and CNS depression risk is dose-dependent; avoid in porphyria. Tolerance develops with prolonged use; withdrawal can be life-threatening. Use as second-line for status epilepticus after benzodiazepines. Highly protein-bound; monitor for interactions with warfarin and oral contraceptives.
Butabarbital is a short-acting barbiturate with a rapid onset; monitor for respiratory depression, especially when combined with other CNS depressants. Use with caution in hepatic impairment due to prolonged half-life. Tolerance and dependence develop with prolonged use; abrupt discontinuation may precipitate withdrawal seizures. Barbiturates induce CYP450 enzymes, potentially reducing efficacy of oral contraceptives, warfarin, and corticosteroids.
Take exactly as prescribed; do not increase dose or frequency.,Avoid alcohol and other CNS depressants (e.g., opioids, benzodiazepines).,Do not drive or operate machinery until you know how this drug affects you.,Do not stop suddenly; abrupt discontinuation can cause withdrawal seizures.,Inform your doctor if you have a history of porphyria, liver disease, or depression.,Use effective contraception; this drug may reduce hormonal contraceptive efficacy.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they may cause severe sedation or respiratory depression.,Do not drive or operate heavy machinery until you know how this medication affects you.,Do not stop taking abruptly; withdrawal can cause anxiety, tremors, and seizures. Taper under medical supervision.,This medication may be habit-forming; store in a safe place to prevent misuse.,Notify your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Inform your doctor of all medications you take, including herbal supplements and over-the-counter drugs.
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
"Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects."
"Butabarbital, a barbiturate, is a potent CNS depressant that acts primarily by potentiating GABA-A receptor activity. Metaxalone is a centrally acting muscle relaxant with sedative properties. Coadministration results in additive or synergistic CNS depression, leading to increased risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential coma or death, especially at higher doses or in vulnerable patients."
"Butabarbital, a barbiturate sedative-hypnotic, induces hepatic cytochrome P450 enzymes, particularly CYP3A4, which are responsible for metabolizing the atypical antipsychotic paliperidone. This induction decreases plasma concentrations of paliperidone, potentially reducing its therapeutic efficacy in treating schizophrenia or bipolar disorder. Concomitant use may lead to relapse of psychiatric symptoms or necessitate dose adjustments."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTABARBITAL SODIUM vs BUTABARB, answered by our medical review team.
BUTABARBITAL SODIUM is a Barbiturate that works by Depresses neuronal activity in the reticular activating system by enhancing GABA-A receptor-mediated chloride influx, increasing the duration of chloride channel opening and inhibiting excitatory neurotransmission at high doses.. BUTABARB is a Barbiturate that works by Barbiturate that binds to GABA-A receptor subunits, potentiating GABAergic inhibition by increasing chloride ion conductance and reducing neuronal excitability.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTABARBITAL SODIUM and BUTABARB depend on the specific clinical indication. These are both Barbiturate agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTABARBITAL SODIUM is: Sedative: 15-30 mg orally 3-4 times daily. Hypnotic: 50-100 mg orally at bedtime. Maximum single dose: 100 mg. Maximum daily dose: 300 mg. Route: oral, intramuscular, intravenous. For IM/IV: divide oral dose by 2.. The standard adult dose of BUTABARB is: 15-30 mg orally 3-4 times daily as needed; maximum 200 mg/day. IV/IM: 50-200 mg for sedation.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BUTABARBITAL SODIUM and BUTABARB. Butabarbital, a barbiturate, induces cytochrome P450 (CYP) enzymes, enhancing the hepatic metabolism of ketamine, a dissociative anesthetic primarily metabolized by CYP3A4 and CYP2B6. This interaction reduces ketamine's systemic exposure and anesthetic efficacy, potentially leading to suboptimal sedation or anesthesia. Additionally, concurrent use may increase the risk of respiratory depression and hypotension due to additive central nervous system (CNS) depressant effects. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BUTABARBITAL SODIUM is classified as Category C. First trimester: Increased risk of major malformations, particularly oral clefts (odds ratio 2.0-3.0). Second trimester: Risk of neural tube defects and cardiac anomalies. Third tr. BUTABARB is classified as Category C. Butabarbital is a barbiturate classified as FDA Pregnancy Category D. First trimester: Increased risk of congenital malformations, particularly oral clefts, neural tube defects, an. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.